Luxturna: What was the first AAV gene therapy approved by the FDA?
•
4 min read
On December 19, 2017, the FDA approved Luxturna, making history as the first AAV gene therapy for a genetic disease in the U.S.. The therapy, developed by Spark Therapeutics, provides a functional gene to treat inherited retinal dystrophy caused by biallelic mutations in the *RPE65* gene.
